NO313878B1 - FremgangsmÕte ved fremstilling av N-(amino-4,6- dihalogenpyrimidin)formamider - Google Patents

FremgangsmÕte ved fremstilling av N-(amino-4,6- dihalogenpyrimidin)formamider Download PDF

Info

Publication number
NO313878B1
NO313878B1 NO19996325A NO996325A NO313878B1 NO 313878 B1 NO313878 B1 NO 313878B1 NO 19996325 A NO19996325 A NO 19996325A NO 996325 A NO996325 A NO 996325A NO 313878 B1 NO313878 B1 NO 313878B1
Authority
NO
Norway
Prior art keywords
diamino
formula
reaction
salts
mol
Prior art date
Application number
NO19996325A
Other languages
English (en)
Norwegian (no)
Other versions
NO996325D0 (no
NO996325L (no
Inventor
Elie Saikali
Walter Brieden
Original Assignee
Lonza Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Ag filed Critical Lonza Ag
Publication of NO996325D0 publication Critical patent/NO996325D0/no
Publication of NO996325L publication Critical patent/NO996325L/no
Publication of NO313878B1 publication Critical patent/NO313878B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO19996325A 1998-12-21 1999-12-20 FremgangsmÕte ved fremstilling av N-(amino-4,6- dihalogenpyrimidin)formamider NO313878B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP98124188 1998-12-21
EP99100788 1999-01-18
EP99107161 1999-04-12
US14610699P 1999-07-29 1999-07-29

Publications (3)

Publication Number Publication Date
NO996325D0 NO996325D0 (no) 1999-12-20
NO996325L NO996325L (no) 2000-06-22
NO313878B1 true NO313878B1 (no) 2002-12-16

Family

ID=27443679

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19996325A NO313878B1 (no) 1998-12-21 1999-12-20 FremgangsmÕte ved fremstilling av N-(amino-4,6- dihalogenpyrimidin)formamider

Country Status (16)

Country Link
US (2) US6271376B1 (ko)
EP (2) EP1188750B1 (ko)
JP (1) JP3543709B2 (ko)
KR (1) KR100645270B1 (ko)
CN (1) CN1156449C (ko)
AT (2) ATE228508T1 (ko)
CA (1) CA2293011C (ko)
CZ (2) CZ296753B6 (ko)
DE (2) DE59907401D1 (ko)
DK (1) DK1013647T3 (ko)
ES (2) ES2204798T3 (ko)
HU (1) HUP9904608A3 (ko)
NO (1) NO313878B1 (ko)
PL (1) PL337354A1 (ko)
PT (1) PT1013647E (ko)
SK (2) SK283681B6 (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208011B2 (en) * 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7208010B2 (en) * 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
GB2344550A (en) * 1998-12-09 2000-06-14 Ibm Pad design for electronic package
EP1582180B1 (en) 2000-10-16 2008-02-27 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US20040204756A1 (en) * 2004-02-11 2004-10-14 Diaz Stephen Hunter Absorbent article with improved liquid acquisition capacity
US7056338B2 (en) * 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US20040249443A1 (en) * 2001-08-20 2004-12-09 Shanley John F. Expandable medical device for treating cardiac arrhythmias
AU2003234670B2 (en) * 2002-05-24 2010-06-10 Angiotech International Ag Compositions and methods for coating medical implants
US20040142014A1 (en) * 2002-11-08 2004-07-22 Conor Medsystems, Inc. Method and apparatus for reducing tissue damage after ischemic injury
KR20130032407A (ko) * 2002-11-08 2013-04-01 코너 메드시스템즈, 엘엘씨 허혈성 상해 후에 조직 손상을 감소시키기 위한 방법 및 장치
JP2006505364A (ja) * 2002-11-08 2006-02-16 コナー メドシステムズ, インコーポレイテッド 血管新生因子の局所供給を用いる、慢性全梗塞を処置するための拡張可能な医療装置および方法
FR2849030A1 (fr) * 2002-12-20 2004-06-25 Isochem Sa Procede de preparation des n-(2-amino-4, 6-dihalogenopyrimidin-5-yl) formamides
US20040202692A1 (en) * 2003-03-28 2004-10-14 Conor Medsystems, Inc. Implantable medical device and method for in situ selective modulation of agent delivery
EP1610823B1 (en) 2003-03-28 2011-09-28 Innovational Holdings, LLC Implantable medical device with continuous agent concentration gradient
US20050010170A1 (en) * 2004-02-11 2005-01-13 Shanley John F Implantable medical device with beneficial agent concentration gradient
WO2004103979A1 (ja) * 2003-05-26 2004-12-02 Sumitomo Chemical Company, Limited N-(2-アミノ-4,6-ジクロロピリミジン-5-イル)ホルムアミドの製造方法
US7208596B2 (en) * 2003-11-25 2007-04-24 Bristol-Myers Squibb Pharma Company Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
US20050287287A1 (en) * 2004-06-24 2005-12-29 Parker Theodore L Methods and systems for loading an implantable medical device with beneficial agent
CN101003511B (zh) * 2007-01-19 2010-06-09 中国科学院上海有机化学研究所 制备2-氨基-4,6-二氯-5-甲酰氨基嘧啶的方法
CZ305457B6 (cs) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
WO2014023681A1 (en) * 2012-08-06 2014-02-13 Enantia, S.L. A process for the preparation of an intermediate for a triazolopyrimidine carbonucleoside
CN103936681B (zh) * 2014-04-04 2015-07-29 苏州开元民生科技股份有限公司 2-氨基-4,6-二氯-5-甲酰胺基嘧啶的制备方法
CN115536595B (zh) * 2022-11-29 2023-03-10 苏州开元民生科技股份有限公司 一种2-氨基-4,6-二氯-5-甲酰胺基嘧啶的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3445293A1 (de) * 1984-12-12 1986-06-12 Bayer Ag, 5090 Leverkusen Neue 2,4-diaminopyrimidine
US4965270A (en) * 1987-05-30 1990-10-23 Beecham Group P.L.C. Purine derivatives
CN1019575B (zh) * 1988-02-19 1992-12-23 石原产业株式会社 2-氨基-4,6-二氯嘧啶的生产方法
DE3900471A1 (de) * 1989-01-10 1990-07-12 Basf Ag Verfahren zur herstellung von 2-amino-4-fluorpyrimidinderivaten
GB8916698D0 (en) * 1989-07-21 1989-09-06 Beecham Group Plc Novel process
SK279618B6 (sk) * 1992-01-22 1999-01-11 Lonza A.G. (Dir.:Basel) N-5-chránené 2,5-diamino-4,6-dichlórpyrimidíny a s
GB9402161D0 (en) * 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
CA2145928C (en) * 1994-04-27 2007-10-09 Gerhard Stucky N-(2-amino-4,6-dichloropyrimidin-5-yl)formamide, and a process for its preparation
AT402924B (de) * 1994-05-13 1997-09-25 Chemie Linz Gmbh Verfahren zur herstellung von 2-amino-4,6-dichloro-pyrimidin

Also Published As

Publication number Publication date
EP1013647A3 (de) 2000-10-04
ES2187112T3 (es) 2003-05-16
JP2000191647A (ja) 2000-07-11
CZ9904598A3 (cs) 2001-03-14
JP3543709B2 (ja) 2004-07-21
HUP9904608A3 (en) 2001-03-28
CZ296832B6 (cs) 2006-06-14
SK178499A3 (en) 2000-09-12
EP1013647A2 (de) 2000-06-28
US6271376B1 (en) 2001-08-07
DK1013647T3 (da) 2003-03-10
CN1265393A (zh) 2000-09-06
EP1013647B1 (de) 2002-11-27
EP1188750A1 (de) 2002-03-20
US6716981B2 (en) 2004-04-06
DE59907401D1 (de) 2003-11-20
EP1188750B1 (de) 2003-10-15
CZ296753B6 (cs) 2006-06-14
US20010031868A1 (en) 2001-10-18
PT1013647E (pt) 2003-04-30
SK285222B6 (sk) 2006-09-07
HU9904608D0 (en) 2000-03-28
NO996325D0 (no) 1999-12-20
CN1156449C (zh) 2004-07-07
KR20000052540A (ko) 2000-08-25
DE59903535D1 (de) 2003-01-09
ATE228508T1 (de) 2002-12-15
HUP9904608A2 (hu) 2000-08-28
PL337354A1 (en) 2000-07-03
ATE252087T1 (de) 2003-11-15
CA2293011A1 (en) 2000-06-21
ES2204798T3 (es) 2004-05-01
KR100645270B1 (ko) 2006-11-13
SK283681B6 (sk) 2003-11-04
CA2293011C (en) 2004-08-10
NO996325L (no) 2000-06-22

Similar Documents

Publication Publication Date Title
NO313878B1 (no) FremgangsmÕte ved fremstilling av N-(amino-4,6- dihalogenpyrimidin)formamider
US6870053B2 (en) Chloropyrimidine intermediates
MXPA96003091A (en) Cloropirimid intermediaries
NO329439B1 (no) Fremgangsmate for fremstilling av kalsiumsaltet fra rosuvastatin
US20090137803A1 (en) 5-protected aminopyrimidine compound, production method thereof and intermediate therefor
FI85856C (fi) Foerfarande foer framstaellning av farmaceutiskt aktiva pyrrolo/3,2-d/pyrimidinoner.
EP1296957A2 (en) Synthesis of chlorinated pyrimidines
WO2008093205A2 (en) A method for the purification of rosuvastatin intermediate
US10669264B2 (en) Process for the preparation of macitentan
US8076479B2 (en) Process and intermediates for the synthesis of (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives and intermediates
CA2182105C (en) Chloropyrimide intermediates
IL129935A (en) Chloropyrimidine intermediates for preparing 2-aminopurine nucleoside analogues and their preparation
WO1993018011A1 (en) Process for the preparation of 2-alkylthio-4-hydrazino-5-fluoropyrimidines
WO1991013064A1 (en) Process for preparing uracil derivatives

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees